CA3155587A1 - Method for treating hiv with cabotegravir and rilpivirine - Google Patents
Method for treating hiv with cabotegravir and rilpivirineInfo
- Publication number
- CA3155587A1 CA3155587A1 CA3155587A CA3155587A CA3155587A1 CA 3155587 A1 CA3155587 A1 CA 3155587A1 CA 3155587 A CA3155587 A CA 3155587A CA 3155587 A CA3155587 A CA 3155587A CA 3155587 A1 CA3155587 A1 CA 3155587A1
- Authority
- CA
- Canada
- Prior art keywords
- salt
- cabotegravir
- rilpivirine
- administered
- intramuscular injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- AIDS & HIV (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962908882P | 2019-10-01 | 2019-10-01 | |
| US201962908995P | 2019-10-01 | 2019-10-01 | |
| US62/908,995 | 2019-10-01 | ||
| US62/908,882 | 2019-10-01 | ||
| US202063037782P | 2020-06-11 | 2020-06-11 | |
| US63/037,782 | 2020-06-11 | ||
| US202063052214P | 2020-07-15 | 2020-07-15 | |
| US63/052,214 | 2020-07-15 | ||
| PCT/IB2020/059185 WO2021064618A1 (en) | 2019-10-01 | 2020-10-01 | Method for treating hiv with cabotegravir and rilpivirine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3155587A1 true CA3155587A1 (en) | 2021-04-08 |
Family
ID=72826936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3155587A Pending CA3155587A1 (en) | 2019-10-01 | 2020-10-01 | Method for treating hiv with cabotegravir and rilpivirine |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20220347174A1 (https=) |
| EP (1) | EP4037661A1 (https=) |
| JP (1) | JP7791083B2 (https=) |
| KR (1) | KR20220074880A (https=) |
| CN (2) | CN118416069A (https=) |
| AU (1) | AU2020358156B2 (https=) |
| CA (1) | CA3155587A1 (https=) |
| CL (1) | CL2022000790A1 (https=) |
| IL (1) | IL290716A (https=) |
| MX (1) | MX2022003945A (https=) |
| WO (1) | WO2021064618A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120053445A (zh) | 2018-07-16 | 2025-05-30 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| WO2023222754A1 (en) * | 2022-05-17 | 2023-11-23 | Janssen Sciences Ireland Unlimited Company | Rilpivirine for use in the treatment or prevention of hiv infection |
| WO2023222755A1 (en) * | 2022-05-17 | 2023-11-23 | Janssen Sciences Ireland Unlimited Company | Treatment or prevention of hiv infection |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2480220T3 (pl) * | 2009-09-22 | 2015-10-30 | Janssen Sciences Ireland Uc | Leczenie i zapobieganie zakażeniu HIV |
| KR20200031658A (ko) * | 2017-07-21 | 2020-03-24 | 비이브 헬쓰케어 컴퍼니 | Hib 감염 및 aids를 치료하기 위한 요법 |
| CN109568328A (zh) * | 2017-09-29 | 2019-04-05 | 重庆药友制药有限责任公司 | 一种用于预防和治疗hiv感染的药物组合物 |
| LT3986561T (lt) * | 2019-06-19 | 2024-04-25 | VIIV Healthcare UK (No.5) Limited | Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai |
-
2020
- 2020-10-01 US US17/763,076 patent/US20220347174A1/en not_active Abandoned
- 2020-10-01 CA CA3155587A patent/CA3155587A1/en active Pending
- 2020-10-01 JP JP2022520291A patent/JP7791083B2/ja active Active
- 2020-10-01 MX MX2022003945A patent/MX2022003945A/es unknown
- 2020-10-01 WO PCT/IB2020/059185 patent/WO2021064618A1/en not_active Ceased
- 2020-10-01 CN CN202410349180.8A patent/CN118416069A/zh active Pending
- 2020-10-01 KR KR1020227010390A patent/KR20220074880A/ko active Pending
- 2020-10-01 EP EP20789687.9A patent/EP4037661A1/en active Pending
- 2020-10-01 CN CN202080069721.1A patent/CN114502166A/zh active Pending
- 2020-10-01 AU AU2020358156A patent/AU2020358156B2/en active Active
-
2022
- 2022-02-17 IL IL290716A patent/IL290716A/en unknown
- 2022-03-30 CL CL2022000790A patent/CL2022000790A1/es unknown
-
2025
- 2025-06-04 US US19/227,593 patent/US20250302829A1/en active Pending
- 2025-06-04 US US19/227,609 patent/US20250302830A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250302830A1 (en) | 2025-10-02 |
| AU2020358156B2 (en) | 2024-06-06 |
| IL290716A (en) | 2022-04-01 |
| WO2021064618A1 (en) | 2021-04-08 |
| EP4037661A1 (en) | 2022-08-10 |
| KR20220074880A (ko) | 2022-06-03 |
| CN118416069A (zh) | 2024-08-02 |
| US20250302829A1 (en) | 2025-10-02 |
| CN114502166A (zh) | 2022-05-13 |
| JP2022550828A (ja) | 2022-12-05 |
| JP7791083B2 (ja) | 2025-12-23 |
| CL2022000790A1 (es) | 2022-11-25 |
| AU2020358156A1 (en) | 2022-04-21 |
| US20220347174A1 (en) | 2022-11-03 |
| MX2022003945A (es) | 2022-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250302830A1 (en) | Method for treating hiv with cabotegravir and rilpivirine | |
| CA3137633A1 (en) | Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof | |
| Dehority et al. | Use of integrase inhibitors in HIV-infected children and adolescents | |
| CA3230291A1 (en) | Dosing regimens associated with extended release paliperidone injectable formulations | |
| TWI879737B (zh) | 利用經取代胺基-嘧啶化合物治療及預防多發性硬化症之方法 | |
| Yu et al. | Pharmacokinetic drug-drug interactions involving antiretroviral agents: an update | |
| Rivera et al. | HIV pre-exposure prophylaxis: new and upcoming drugs to address the HIV epidemic | |
| US12011506B2 (en) | Combination and uses and treatments thereof | |
| Dirajlal-Fargo et al. | Pediatric antiretroviral therapy | |
| US10085996B2 (en) | Pharmaceutical combinations | |
| RU2840867C1 (ru) | Способ лечения вич каботегравиром и рилпивирином | |
| US20210290590A1 (en) | Methods of treating subjects infected with hiv | |
| US20240091159A1 (en) | Combination and Uses and Treatments Thereof | |
| US20220096487A1 (en) | Methods for treating hiv with dolutegravir and lamivudine | |
| Vanangamudi et al. | Current and Promising Multiclass Drug Regimens and Long-Acting Formulation Drugs in HIV Therapy | |
| Ballon | New drugs | |
| Tablets et al. | Antiretroviral Agent | |
| WO2026050513A1 (en) | Tolebrutinib for multiple sclerosis | |
| AU2024318637A1 (en) | Obefazimod for treatment of ulcerative colitis | |
| Tablets | FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE | |
| Venter et al. | Stavudine | |
| WO2014193589A1 (en) | Cancer treatment method | |
| Merai et al. | New Approaches to Antiretroviral Therapy-Raltigravir | |
| Blonk et al. | and David M. Burger | |
| Koren et al. | HIV Pharmacotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240924 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240924 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240924 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241001 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241001 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241120 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241209 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241209 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250422 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250923 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250923 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251021 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260223 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260224 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260224 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260224 |